150 related articles for article (PubMed ID: 26135933)
1. Tissue Chromogranin A Expression during Prostate Cancer Progression: Prediction of Chemosensitivity.
Mitsui Y; Arichi N; Hiraki M; Harada Y; Yasumoto H; Shiina H
Urol J; 2015 Jul; 12(3):2165-72. PubMed ID: 26135933
[TBL] [Abstract][Full Text] [Related]
2. Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer.
Narita S; Tsuchiya N; Yuasa T; Maita S; Obara T; Numakura K; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
Int J Clin Oncol; 2012 Jun; 17(3):204-11. PubMed ID: 21706123
[TBL] [Abstract][Full Text] [Related]
3. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.
Loriot Y; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Bossi A; Fizazi K
Ann Oncol; 2009 Apr; 20(4):703-8. PubMed ID: 19179557
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
5. Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy.
Sarkar D; Singh SK; Mandal AK; Agarwal MM; Mete UK; Kumar S; Mavuduru RS; Prasad R
Cancer Biomark; 2010-2011; 8(2):81-7. PubMed ID: 21896995
[TBL] [Abstract][Full Text] [Related]
6. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
8. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
Burgio SL; Conteduca V; Menna C; Carretta E; Rossi L; Bianchi E; Kopf B; Fabbri F; Amadori D; De Giorgi U
Endocr Relat Cancer; 2014 Jun; 21(3):487-93. PubMed ID: 24741024
[TBL] [Abstract][Full Text] [Related]
9. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
10. Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.
Nordin A; Wang W; Welén K; Damber JE
Prostate; 2013 May; 73(6):657-67. PubMed ID: 23129424
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis.
Song P; Huang C; Wang Y
Int J Surg; 2018 Aug; 56():133-140. PubMed ID: 29906643
[TBL] [Abstract][Full Text] [Related]
13. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Du J; Yang Q; Chen XS; Tian J; Yao X
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
[TBL] [Abstract][Full Text] [Related]
15. Chromogranin A: a useful biomarker in castration-resistant prostate cancer.
Ploussard G; Rozet F; Roubaud G; Stanbury T; Sargos P; Roupret M
World J Urol; 2023 Feb; 41(2):361-369. PubMed ID: 36527470
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
Sella A; Sternberg CN; Skoneczna I; Kovel S
BJU Int; 2008 Dec; 102(11):1607-9. PubMed ID: 18990177
[TBL] [Abstract][Full Text] [Related]
17. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
[TBL] [Abstract][Full Text] [Related]
18. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients.
Komiya A; Yasuda K; Watanabe A; Fujiuchi Y; Tsuzuki T; Fuse H
Mol Clin Oncol; 2013 Mar; 1(2):257-262. PubMed ID: 24649157
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer.
Sella A; Yarom N; Zisman A; Kovel S
Oncology; 2009; 76(6):442-6. PubMed ID: 19420966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
